Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jigna Shah

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Cellular Signalling|November 15, 2024
Antagonists of CD39 and CD73 potentiate doxycycline repositioning to induce a potent antitumor immune responseParameswar Dalai, Dhruvi Shah, Jigna Shah, et al.
Toxicology Mechanisms and Methods|March 11, 2024
Neuroprotective effect of taxifolin against aluminum chloride-induced dementia and pathological alterations in the brain of rats: possible involvement of toll-like receptor 4Bhagawati Saxena, Pragnesh Parmar, Heena Chauhan, et al.
Journal of Biomaterials Science. Polymer Edition|March 2, 2016
Dendrimer-mediated approaches for the treatment of brain tumorNitin Dwivedi, Jigna Shah, Vijay Mishra, et al.
Scientific Reports|July 9, 2016
Salmonella Degrades the Host Glycocalyx Leading to Altered Infection and Glycan RemodelingNarine Arabyan, Dayoung Park, Soraya Foutouhi, et al.
Frontiers in Cell and Developmental Biology|April 3, 2023
<i>Salmonella</i> enhances osteogenic differentiation in adipose-derived mesenchymal stem cellsNuradilla Mohamad-Fauzi, Claire Shaw, Soraya H Foutouhi, et al.
Breast Cancer Research : BCR|November 21, 2013
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumorsClifford Hudis, Charles Swanton, Yelena Y Janjigian, et al.
The Lancet. Oncology|October 1, 2020
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trialLeisha A Emens, Francisco J Esteva, Mark Beresford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN StudyIan E Krop, Seock-Ah Im, Carlos Barrios, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Cellular Signalling|November 15, 2024
Antagonists of CD39 and CD73 potentiate doxycycline repositioning to induce a potent antitumor immune responseParameswar Dalai, Dhruvi Shah, Jigna Shah, et al.
Toxicology Mechanisms and Methods|March 11, 2024
Neuroprotective effect of taxifolin against aluminum chloride-induced dementia and pathological alterations in the brain of rats: possible involvement of toll-like receptor 4Bhagawati Saxena, Pragnesh Parmar, Heena Chauhan, et al.
Journal of Biomaterials Science. Polymer Edition|March 2, 2016
Dendrimer-mediated approaches for the treatment of brain tumorNitin Dwivedi, Jigna Shah, Vijay Mishra, et al.
Scientific Reports|July 9, 2016
Salmonella Degrades the Host Glycocalyx Leading to Altered Infection and Glycan RemodelingNarine Arabyan, Dayoung Park, Soraya Foutouhi, et al.
Frontiers in Cell and Developmental Biology|April 3, 2023
<i>Salmonella</i> enhances osteogenic differentiation in adipose-derived mesenchymal stem cellsNuradilla Mohamad-Fauzi, Claire Shaw, Soraya H Foutouhi, et al.
Breast Cancer Research : BCR|November 21, 2013
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumorsClifford Hudis, Charles Swanton, Yelena Y Janjigian, et al.
The Lancet. Oncology|October 1, 2020
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trialLeisha A Emens, Francisco J Esteva, Mark Beresford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN StudyIan E Krop, Seock-Ah Im, Carlos Barrios, et al.
Pageof 5